Engineering Cell Lines for Specific Human Leukocyte Antigen Presentation

Overview

Journal Methods Mol Biol

Specialty Molecular Biology

Date 2023 Jun 24

PMID 37355557

Authors

Dongbin Jin

Khai Lee Loh

Tima Shamekhi

Yi Tian Ting

Terry C C Lim Kam Sian

James Roest

Joshua D Ooi

Julian P Vivian

Pouya Faridi

Affiliations

Soon will be listed here.

Abstract

Epitope-specific immunotherapies have enabled the targeted treatment of a variety of diseases, ranging from cancer, infection, and autoimmune disorders. For CD8 T cell-based therapies, the precise identification of immunogenic peptides presented by human leukocyte antigen (HLA) class I is essential which can be achieved by immunopeptidomics. Here, using lentivirus-mediated transduction and cell sorting approaches, we present a method to engineer a cell line that does not express its native HLA but instead expresses an HLA of interest (in this instance HLA-A*02:01). This technique can be used to elucidate the immunopeptidome of cell lines expressing different HLAs.

References

Herceg Z, Hainaut P . Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis. Mol Oncol. 2009; 1(1):26-41. PMC: 5543860. DOI: 10.1016/j.molonc.2007.01.004. View

Chong C, Coukos G, Bassani-Sternberg M . Identification of tumor antigens with immunopeptidomics. Nat Biotechnol. 2021; 40(2):175-188. DOI: 10.1038/s41587-021-01038-8. View

Leon-Letelier R, Katayama H, Hanash S . Mining the Immunopeptidome for Antigenic Peptides in Cancer. Cancers (Basel). 2022; 14(20). PMC: 9599891. DOI: 10.3390/cancers14204968. View

Croft N, Smith S, Pickering J, Sidney J, Peters B, Faridi P . Most viral peptides displayed by class I MHC on infected cells are immunogenic. Proc Natl Acad Sci U S A. 2019; 116(8):3112-3117. PMC: 6386720. DOI: 10.1073/pnas.1815239116. View

Dersh D, Holly J, Yewdell J . A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion. Nat Rev Immunol. 2020; 21(2):116-128. DOI: 10.1038/s41577-020-0390-6. View

Prinz J . Immunogenic self-peptides - the great unknowns in autoimmunity: Identifying T-cell epitopes driving the autoimmune response in autoimmune diseases. Front Immunol. 2023; 13:1097871. PMC: 9868241. DOI: 10.3389/fimmu.2022.1097871. View

Jones E, Barnstable C, Solomon E, Bodmer W . The genetic control of HLA-A and B antigens in somatic cell hybrids: requirement for beta2 microglobulin. Tissue Antigens. 1978; 11(2):96-112. DOI: 10.1111/j.1399-0039.1978.tb01233.x. View

Sugita M, Brenner M . An unstable beta 2-microglobulin: major histocompatibility complex class I heavy chain intermediate dissociates from calnexin and then is stabilized by binding peptide. J Exp Med. 1994; 180(6):2163-71. PMC: 2191763. DOI: 10.1084/jem.180.6.2163. View

Mottez E, Jaulin C, Godeau F, Choppin J, LEVY J, Kourilsky P . A single-chain murine class I major transplantation antigen. Eur J Immunol. 1991; 21(2):467-71. DOI: 10.1002/eji.1830210232. View

10.

Lee L, McHugh L, Ribaudo R, Kozlowski S, Margulies D, Mage M . Functional cell surface expression by a recombinant single-chain class I major histocompatibility complex molecule with a cis-active beta 2-microglobulin domain. Eur J Immunol. 1994; 24(11):2633-9. DOI: 10.1002/eji.1830241110. View

11.

Toshitani K, Braud V, Browning M, Murray N, McMichael A, Bodmer W . Expression of a single-chain HLA class I molecule in a human cell line: presentation of exogenous peptide and processed antigen to cytotoxic T lymphocytes. Proc Natl Acad Sci U S A. 1996; 93(1):236-40. PMC: 40213. DOI: 10.1073/pnas.93.1.236. View

12.

Yu Y, Netuschil N, Lybarger L, Connolly J, Hansen T . Cutting edge: single-chain trimers of MHC class I molecules form stable structures that potently stimulate antigen-specific T cells and B cells. J Immunol. 2002; 168(7):3145-9. DOI: 10.4049/jimmunol.168.7.3145. View

13.

Kotsiou E, Brzostek J, Gould K . Properties and applications of single-chain major histocompatibility complex class I molecules. Antioxid Redox Signal. 2010; 15(3):645-55. PMC: 3125553. DOI: 10.1089/ars.2010.3694. View

14.

DUrso C, Wang Z, Cao Y, Tatake R, Zeff R, Ferrone S . Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest. 1991; 87(1):284-92. PMC: 295046. DOI: 10.1172/JCI114984. View

15.

Hoerster K, Uhrberg M, Wiek C, Horn P, Hanenberg H, Heinrichs S . HLA Class I Knockout Converts Allogeneic Primary NK Cells Into Suitable Effectors for "Off-the-Shelf" Immunotherapy. Front Immunol. 2021; 11:586168. PMC: 7878547. DOI: 10.3389/fimmu.2020.586168. View

16.

Zhang Y, Wang Y, Shao L, Pan X, Liang C, Liu B . Knockout of beta-2 microglobulin reduces stem cell-induced immune rejection and enhances ischaemic hindlimb repair via exosome/miR-24/Bim pathway. J Cell Mol Med. 2019; 24(1):695-710. PMC: 6933348. DOI: 10.1111/jcmm.14778. View

17.

Zheng D, Wang X, Zhang Z, Li E, Yeung C, Borkar R . Engineering of human mesenchymal stem cells resistant to multiple natural killer subtypes. Int J Biol Sci. 2022; 18(1):426-440. PMC: 8692142. DOI: 10.7150/ijbs.64640. View

18.

Lee N, Llano M, Carretero M, Ishitani A, Navarro F, Lopez-Botet M . HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci U S A. 1998; 95(9):5199-204. PMC: 20238. DOI: 10.1073/pnas.95.9.5199. View

19.

Favier B, LeMaoult J, Lesport E, Carosella E . ILT2/HLA-G interaction impairs NK-cell functions through the inhibition of the late but not the early events of the NK-cell activating synapse. FASEB J. 2009; 24(3):689-99. DOI: 10.1096/fj.09-135194. View

20.

Gornalusse G, Hirata R, Funk S, Riolobos L, Lopes V, Manske G . HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nat Biotechnol. 2017; 35(8):765-772. PMC: 5548598. DOI: 10.1038/nbt.3860. View